CCT020312 Inhibits Triple-Negative Breast Cancer Through PERK Pathway-Mediated G1 Phase Cell Cycle Arrest and Apoptosis

Triple-negative breast cancer (TNBC) has a poor prognosis due to the lack of specific therapeutic targets. CCT020312, a selective eukaryotic translation initiation factor 2 alpha (eIF2α)/protein kinase RNA-like endoplasmic reticulum kinase (PERK) activator, may have a potent anti-tumor effect. In th...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Front Pharmacol
Autori principali: Li, Xiaoli, Yu, Xiaoping, Zhou, Duanfang, Chen, Bo, Li, Wenjun, Zheng, Xiangru, Zeng, Hongfang, Long, Liangyuan, Zhou, Weiying
Natura: Artigo
Lingua:Inglês
Pubblicazione: Frontiers Media S.A. 2020
Soggetti:
Pharmacology
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7250150/
https://ncbi.nlm.nih.gov/pubmed/32508655
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2020.00737
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi